|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM205444318 |
| 003 |
DE-627 |
| 005 |
20231223233948.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.12.006
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0685.xml
|
| 035 |
|
|
|a (DE-627)NLM205444318
|
| 035 |
|
|
|a (NLM)21276756
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Crowder, Roslyn N
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a B lymphocytes are resistant to death receptor 5-induced apoptosis
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.06.2011
|
| 500 |
|
|
|a Date Revised 20.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Published by Elsevier Inc.
|
| 520 |
|
|
|a Death Receptor 5 (DR5) induces apoptosis in various types of cells and is a potential therapeutic target. We have investigated whether targeting DR5 could be used to eliminate pathogenic B lymphocytes from systemic lupus erythematosus (SLE) patients. We examined DR5 expression and function on B lymphocytes from healthy controls subjects, SLE patients, and human tonsil. DR5 was expressed similarly on all B cell subpopulations, including resting and activated B cells. Expression of DR5 was equivalent on B cells from SLE patients and healthy subjects. Additionally, DR5 expression was unchanged after B lymphocyte stimulation. However, B cells were resistant to DR5-induced apoptosis, including after in vitro activation. No changes in subsets of B cells were observed in subjects of a trial of CS-1008, an agonist anti-DR5. While DR5 shows promise as a way to selectively eliminate tumor cells and activated synoviocytes, these data suggest DR5 alone cannot be used as a target to remove pathogenic SLE B cells
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Receptors, TNF-Related Apoptosis-Inducing Ligand
|2 NLM
|
| 700 |
1 |
|
|a Zhao, Hong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chatham, W Winn
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Tong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Carter, Robert H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 139(2011), 1 vom: 08. Apr., Seite 21-31
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:139
|g year:2011
|g number:1
|g day:08
|g month:04
|g pages:21-31
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.12.006
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 139
|j 2011
|e 1
|b 08
|c 04
|h 21-31
|